NorthStar Trial Analysis at ELCC 2026: Local Consolidative Therapy in EGFR-Mutant NSCLC
oncodaily - The management of metastatic EGFR-mutant non-small cell lung cancer (NSCLC) has been transformed by the introduction of third-generation EGFR tyrosine kinase inhibitors, particularly osimertinib. While systemic therapy achieves meaningful disease […]
AI Summary: ELCC 2026 brought together clinicians and investigators to present pivotal lung‑cancer studies, including localized consolidative therapy, SBRT sequencing with immunotherapy, and trials addressing under‑represented KRAS and EGFR populations. The conference highlighted survival and tumor‑control signals, networked international collaborators, and emphasized real‑world applicability — proving once again that conferences are where hope meets peer review.
- At ELCC: late‑breaking trials reshaping clinical practice (6)
- OTHER: misc lung oncology studies, regulatory and surgical updates (8)
- Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care (6)
- Voices from ELCC: clinicians share breakthroughs and practical takeaways (17)
- All Other Stories
At ELCC: late‑breaking trials reshaping clinical practice
OTHER: misc lung oncology studies, regulatory and surgical updates
Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care
Voices from ELCC: clinicians share breakthroughs and practical takeaways
All Other Stories
Spatial mapping technique allows researchers to understand tumor architecture
medicalxpress - Tumors contain many different types of cells organized in complex spatial patterns that can influence how the disease progresses. Because of this, it is hard to predict how a tumor will develop and respond to treatment. Researchers at the University of Il…
AI Summary: Advanced spatial mapping techniques revealed how tumor architecture and local microenvironments reorganize — including changes driven by tumor‑linked viruses — altering immune cell positioning and signaling. The work provides a high‑resolution blueprint for understanding treatment resistance and suggests new targets for precision therapies that consider the tumor’s geographic biology, not just its genetics.
- Field report: Immune geography dictates therapy response and resistance (4)
- On scene: microbes and viruses remap tumor microenvironments (3)
- On the ground: spatial multi-omics maps tumor architecture (4)
- Other: Miscellaneous tumor biology, therapies, biomarkers (18)
- All Other Stories
Field report: Immune geography dictates therapy response and resistance
On scene: microbes and viruses remap tumor microenvironments
On the ground: spatial multi-omics maps tumor architecture
Other: Miscellaneous tumor biology, therapies, biomarkers
All Other Stories
A gut microbe linked to the Mediterranean diet boosts muscle strength in mice
livescience - Researchers are exploring the prospect of using gut bacteria to boost muscle strength, after zeroing in on a microbe that does this in mice
AI Summary: Researchers identified a gut microbe associated with adherence to a Mediterranean-style diet that, when introduced to mice, improved muscle strength and mitochondrial-related signals. The findings suggest a microbiome-mediated pathway that could inform interventions for age-related muscle decline, though translation to humans remains unproven and will need careful clinical follow-up.
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
Lei Lei Wu / endpoints - New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma in some patients, it may not be safer than the ...
AI Summary: Early reports from a phase 1 in‑vivo CAR‑T program show promising anti‑myeloma activity following direct in‑body CAR induction targeting BCMA, but investigators also reported a treatment‑related death in a China trial. The mixed signals underscore the potential of in‑vivo CAR approaches while spotlighting safety, dosing and monitoring challenges that must be resolved before wider adoption.
- AstraZeneca's in‑vivo CAR‑T: early wins, serious safety questions (4)
- Myeloma community reacts: experts, conferences and paper highlights (7)
- Next‑gen T‑cell strategies and regulatory hurdles (4)
- All Other Stories
AstraZeneca's in‑vivo CAR‑T: early wins, serious safety questions
Myeloma community reacts: experts, conferences and paper highlights
Next‑gen T‑cell strategies and regulatory hurdles
All Other Stories
EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib
esmo - It is intended for the treatment of paediatric patients with low-grade glioma with BRAF alterations whose disease has progressed after one or more prior systemic therapies
AI Summary: Five‑year results from KEYNOTE‑671 indicate perioperative pembrolizumab yields sustained clinical benefit in early‑stage non‑small‑cell lung cancer, improving outcomes even when pathological complete response is not achieved. The data bolster the case for integrating immune checkpoint blockade into surgical-era treatment strategies, shifting conversations about neoadjuvant and adjuvant sequencing.
- Frontline precision: KRAS G12D and EGFR targeted advances in NSCLC (4)
- Insider view: evolving IO biology, toxicity and access debates (3)
- On-the-ground: Neoadjuvant immunotherapy and radiotherapy reshaping lung surgery (4)
- OTHER: assorted oncology updates outside perioperative NSCLC focus (4)
- All Other Stories
Frontline precision: KRAS G12D and EGFR targeted advances in NSCLC
Insider view: evolving IO biology, toxicity and access debates
On-the-ground: Neoadjuvant immunotherapy and radiotherapy reshaping lung surgery
OTHER: assorted oncology updates outside perioperative NSCLC focus
All Other Stories
J. Michael Bishop, Nobel Prize Winner for Cancer Research, Dies at 90
Delthia Ricks / nytimes - He helped discover cancer-causing genes. Later, as chancellor of the University of California, San Francisco, he led a major expansion.
AI Summary: J. Michael Bishop, Nobel Prize–winning cancer researcher, has died at 90. Colleagues recall his transformative work illuminating oncogenes and reshaping cancer biology, plus a career of mentorship that seeded generations of scientists. The obituaries and memorial pieces celebrate both his landmark discoveries and the enduring institutions and researchers he helped build.
Two States Sue Cord Blood Bank Over False Advertisements
Sarah Kliff and Azeen Ghorayshi / nytimes - The attorneys general of Texas and Arizona contend that Cord Blood Registry, which stores umbilical cord cells, profited from misleading new parents.
AI Summary: Two state attorneys general filed lawsuits alleging a cord‑blood bank made false or misleading claims about the future therapeutic value of stored units. The actions seek consumer remedies and penalties, challenging marketing that regulators say may have led families to pay for services based on overstated promises about potential medical uses.
“Me engañaron”: agentes encadenan a un padre que había ido al ICE a reunirse con sus hijos
Claudia Boyd-Barrett and Renuka Rayasam and Amanda Seitz / kffhealthnews - Se supone que la agencia que cuida a niños que llegan solos al país deben reunirlos pronto con sus familias o cuidadores. Pero cada vez más los usan como “carnada” para arrestar a los padres.
AI Summary: Gilead struck a deal to acquire Ouro Medicines for roughly $1.68–1.7 billion, securing an immune‑modulating autoimmune program intended to reset pathological immune responses. The transaction combines upfront cash and potential milestones, expanding Gilead’s pipeline and signaling continued industry appetite for bolt‑on buys to chase novel therapeutics.
Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia
esmo - Findings from the RECITE study
AI Summary: A clinical study found romiplostim effective in treating and preventing recurrent persistent chemotherapy‑induced thrombocytopenia, restoring platelet counts and enabling continuation of scheduled cytotoxic therapy. Patients experienced fewer delays and dose reductions, positioning romiplostim as a useful strategy to keep chemo on track—because, apparently, platelet math still runs cancer care.
Results from the Phase 2 POLAR Trial: Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer
oncodaily - Pancreatic cancer remains one of the most challenging malignancies to treat, particularly in the metastatic setting, where immunotherapy has historically shown minimal activity. However, a biologically defined subset of patients […]
AI Summary: The Phase 2 POLAR trial presented results evaluating pembrolizumab combined with olaparib in homologous recombination–deficient metastatic pancreatic cancer, including safety, response rates and biomarker analyses. Investigators observed signals of activity in HRD‑selected patients, suggesting the immunotherapy–PARP inhibitor combination merits larger randomized testing rather than immediate headline glory.
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong
abcnews - Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's cancer drugs
AI Summary: The FDA issued warnings over promotional materials and public statements related to a cancer drug associated with a biotech entrepreneur, finding claims that could mislead patients and investors. The agency asked the company to correct materials and refrain from unsubstantiated efficacy or safety assertions while oversight and compliance reviews continue.
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs
Frank Vinluan / medcitynews - Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier. The post FDA Approval for …
AI Summary: Regulators granted Denali accelerated approval for a brain‑penetrant therapy, recognizing promising early efficacy in a rare neurological indication and addressing unmet needs in CNS drug delivery. The pathway requires confirmatory trials to verify clinical benefit while enabling earlier patient access to a novel mechanism targeting central nervous system disease.
FDA approves 1st weekly basal insulin for Type 2 diabetes
Ella Jeffries / beckershospitalreview - The FDA has approved Novo Nordisk’s Awiqli (insulin icodec-abae), making it the first once-weekly basal insulin available in the U.S. for adults with Type 2 diabetes. Awiqli is indicated as an adjunct to diet and exercise and is intended to reduce injecti…
AI Summary: The FDA approved the first once‑weekly basal insulin for adults with Type 2 diabetes, providing an alternative to daily injections and aiming to improve adherence and glycemic control. Regulators based the decision on trials showing comparable efficacy and safety to daily basal insulins, potentially reshaping diabetes management.
FDA approves Rocket's gene therapy for ultra-rare immune disease
Lei Lei Wu / endpoints - A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated approval to Rocket Pharma’s gene therapy ...
AI Summary: The FDA granted approval to Rocket’s gene therapy for a pediatric immune disorder, marking the first regulatory ok for this specific treatment class in children and offering a one‑time corrective option for affected patients. The decision opens access while raising expectations for long‑term follow‑up and real‑world safety monitoring.
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug
Frank Vinluan / medcitynews - Merck has been acquiring assets that could help make up for the coming revenue decline as its top product, the cancer drug Keytruda, drops off the patent cliff. Terns Pharmaceuticals’ lead product candidate, in development for treating a type of leukemia,…
AI Summary: Merck announced a definitive deal to acquire Terns Pharmaceuticals for about $6.7 billion, gaining a promising leukemia drug candidate and bolstering its oncology pipeline. The transaction aims to combine Merck’s late‑stage development and commercialization capabilities with Terns’ targeted therapy assets to compete in hematologic malignancies.
Pfizer Lyme vaccine candidate heads to FDA
Ella Jeffries / beckershospitalreview - Pfizer and Valneva’s investigational Lyme disease vaccine candidate, PF-07307405 (LB6V), demonstrated more than 70% efficacy in preventing Lyme disease among individuals age 5 and older, according to topline phase 3 trial results. The prespecified analysi…
AI Summary: Pfizer is advancing a Lyme disease vaccine toward FDA submission despite a messy late‑stage picture: efficacy signals above 70% were reported while a pivotal trial missed its primary endpoint and struggled with low case numbers. Regulators must weigh public health need against statistical nuance as the company pushes for licensure.
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Ayisha Sharma / endpoints - Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar target, but drugmakers are now entering the next-generation era as ...
AI Summary: Novartis agreed to pay $2 billion upfront to acquire Synnovation’s mutant‑selective PI3Kα inhibitor, a bet to revive and strengthen PI3K‑targeting combination strategies in breast cancer. The deal swaps in external innovation for internal development speed, shoring up the company’s oncology pipeline while quietly admitting buying is sometimes faster than building.
A blood test may tailor breast cancer treatment for older women
medicalxpress - For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions. In a study published today in Clinical …
AI Summary: An ultra‑sensitive circulating tumor DNA assay shows promise in tailoring treatment for older breast cancer patients by detecting molecular signals that could guide therapy decisions and avoid unnecessary interventions. The blood test aims to refine risk stratification and personalize care where standard approaches often lack nuance, potentially sparing frail patients from overtreatment.
- EBCC15: Less overtreatment through personalized radiotherapy and surveillance (4)
- Liquid biopsies and sensors advancing cancer detection beyond breast (4)
- Other: biology and global burden stories (3)
- Ultrasensitive ctDNA: tailoring breast cancer care for older patients (5)
- All Other Stories
EBCC15: Less overtreatment through personalized radiotherapy and surveillance
Liquid biopsies and sensors advancing cancer detection beyond breast
Other: biology and global burden stories
Ultrasensitive ctDNA: tailoring breast cancer care for older patients
All Other Stories
Vivek Subbiah: New Nature Study on Thymic Health and Response
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow published in NATURE journal ‘Thymic health and immunotherapy outcomes in patients […]
AI Summary: A new Nature study reveals that adult thymic health materially affects immune aging and responses to cancer treatment. Researchers show thymic integrity correlates with stronger immune surveillance and better therapy outcomes, reviving interest in thymus-targeted interventions. Experts describe the finding as a necessary reappraisal of an organ long written off by adult medicine — cue the applause.
- Aging immunity: why older immune systems fail us (5)
- Front lines: new targets and tactics in cancer immunotherapy (9)
- On the ground: adult thymus drives longevity and therapy success (5)
- All Other Stories
Aging immunity: why older immune systems fail us
Front lines: new targets and tactics in cancer immunotherapy
On the ground: adult thymus drives longevity and therapy success
All Other Stories
TerraPower Isotopes Invests $450M in Actinium-225 Production Facility
oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…
AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.